Advances on clinical researches of cerebrovascular diseases in 2017_West China Medical Journal

Authors：

YAN Yuying ,  WU Bo , LIU Ming

Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

WU Bo, Email: dragonwbtxf@hotmail.com

Keywords：

Cerebral vascular diseases; Thrombolysis treatment; Antiplatelet treatment

DOI：

10.7507/1002-0179.201805155

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Substantial progresses have been made in cerebral vascular diseases in 2017. By retrospectively analyzing the clinical researches which Chinese experts participated in or were in charge of, this article briefly summarizes the update of stroke epidemiology, explorations of stroke-related risk factors, early management of acute stroke, secondary prevention and prognosis of stroke. These researches include the problems about the dose of thrombolysis medicine, new type of antiplatelet and anticoagulant drugs, prognosis of intracranial hemorrhage and signs of intracranial hematoma enlargement, which have close connection with clinical work and are valuable in practice.

Citation： YAN Yuying, WU Bo, LIU Ming. Advances on clinical researches of cerebrovascular diseases in 2017. West China Medical Journal, 2018, 33(6): 635-638. doi: 10.7507/1002-0179.201805155 Copy

1.	Guan TJ, Ma J, Li M, et al. Rapid transitions in the epidemiology of stroke and its risk factors in China from 2002 to 2013. Neurology, 2017, 89(1): 53-61.
2.	Huang X, Li YB, Li P, et al. Association between percent decline in serum total homocysteine and risk of first stroke. Neurology, 2017, 89(20): 2101-2107.
3.	Ma C, Pavlova M, Liu Y, et al. Probable REM sleep behavior disorder and risk of stroke: a prospective study. Neurology, 2017, 88(19): 1849-1855.
4.	Juan J, Liu G, Willett WC, et al. Whole grain consumption and risk of ischemic stroke: results from 2 prospective cohort studies. Stroke, 2017, 48(12): 3203-3209.
5.	Lin H, Guo Y, Di Q, et al. Ambient PM2.5 and stroke: effect modifiers and population attributable risk in six low- and middle-income countries. Stroke, 2017,48(5):1191-1197.
6.	Pan YE, Meng X, Jing J, et al. Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA. Neurology, 2017, 88(11): 1081-1088.
7.	Pan Y, Chen W, Jing J, et al. Pancreatic β-cell function and prognosis of nondiabetic patients with ischemic stroke. Stroke, 2017, 48(11): 2999-3005.
8.	Jing J, Pan YE, Zhao XQ, et al. Insulin resistance and prognosis of nondiabetic patients with ischemic stroke the ACROSS-China study (abnormal glucose regulation in patients with acute stroke across China) Stroke, 2017, 48(4): 887-893.
9.	Wang X, Robinson TG, Lee TH, et al. Low-dose vs standard-dose alteplase for patients with acute ischemic stroke secondary analysis of the ENCHANTED randomized clinical trial. JAMA Neurol, 2017, 74(11): 1328-1335.
10.	Robinson TG, Wang X, Arima H, et al. Low- versus standard-dose alteplase in patients on prior antiplatelet therapy the ENCHANTED trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study). Stroke, 2017, 48(7): 1877-1883.
11.	Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med, 2016, 375(1): 35-43.
12.	Wang YJ, Minematsu K, Wong KS, et al. Ticagrelor in acute stroke or transient ischemic attack in Asian patients: from the SOCRATES trial (acute stroke or transient ischemic attack treated with aspirin or ticagrelor and patient outcomes). Stroke, 2017, 48(1): 167-173.
13.	Amarenco P, Albers GW, Denison H, et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol, 2017, 16(4): 301-310.
14.	Amarenco P, Albers GW, Denison H, et al. Ticagrelor versus aspirin in acute embolic stroke of undetermined source. Stroke, 2017, 48(9): 2480-2487.
15.	Wang Y, Zhao X, Lin J, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA, 2016, 316(1): 70-78.
16.	Lin Y, Wang A, Li J, et al. Impact of glycemic control on efficacy of clopidogrel in transient ischemic attack or minor stroke patients with CYP2C19 genetic variants. Stroke, 2017, 48(4): 998-1004.
17.	Ernst A, Schlattmann P, Waldfahrer F, et al. 13 Age-specific trends of atrial fibrillation-related ischaemic stroke and transient ischaemic attack,anticoagulant use and risk factor profile in Chinese population--a 15-year study. Laryngorhinootologie, 2017, 96(8): 519-521.
18.	Bai Y, Deng H, Shantsila A, et al. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and Meta-analysis. Stroke, 2017, 48(4): 970-976.
19.	Anderson CS, Huang Y, Arima H, et al. Effects of early intensive blood pressure-lowering treatment on the growth of hematoma and perihematomal edema in acute intracerebral hemorrhage: the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT). Stroke, 2010, 41(2): 307-312.
20.	Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med, 2013, 368(25): 2355-2365.
21.	Delcourt C, Sato S, Zhang SH, et al. Intracerebral hemorrhage location and outcome among INTERACT2 participants. Neurology, 2017, 88(15): 1408-1414.
22.	Moullaali TJ, Sato S, Wang X, et al. Prognostic significance of delayed intraventricular haemorrhage in the interact studies. J Neurol Neurosurg Psychiatry, 2017, 88(1): 19-24.
23.	Li Q, Liu QJ, Yang WS, et al. Island sign: an imaging predictor for early hematoma expansion and poor outcome in patients with intracerebral hemorrhage. Stroke, 2017, 48(11): 3019-3025.

1. Guan TJ, Ma J, Li M, et al. Rapid transitions in the epidemiology of stroke and its risk factors in China from 2002 to 2013. Neurology, 2017, 89(1): 53-61.
2. Huang X, Li YB, Li P, et al. Association between percent decline in serum total homocysteine and risk of first stroke. Neurology, 2017, 89(20): 2101-2107.
3. Ma C, Pavlova M, Liu Y, et al. Probable REM sleep behavior disorder and risk of stroke: a prospective study. Neurology, 2017, 88(19): 1849-1855.
4. Juan J, Liu G, Willett WC, et al. Whole grain consumption and risk of ischemic stroke: results from 2 prospective cohort studies. Stroke, 2017, 48(12): 3203-3209.
5. Lin H, Guo Y, Di Q, et al. Ambient PM2.5 and stroke: effect modifiers and population attributable risk in six low- and middle-income countries. Stroke, 2017,48(5):1191-1197.
6. Pan YE, Meng X, Jing J, et al. Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA. Neurology, 2017, 88(11): 1081-1088.
7. Pan Y, Chen W, Jing J, et al. Pancreatic β-cell function and prognosis of nondiabetic patients with ischemic stroke. Stroke, 2017, 48(11): 2999-3005.
8. Jing J, Pan YE, Zhao XQ, et al. Insulin resistance and prognosis of nondiabetic patients with ischemic stroke the ACROSS-China study (abnormal glucose regulation in patients with acute stroke across China) Stroke, 2017, 48(4): 887-893.
9. Wang X, Robinson TG, Lee TH, et al. Low-dose vs standard-dose alteplase for patients with acute ischemic stroke secondary analysis of the ENCHANTED randomized clinical trial. JAMA Neurol, 2017, 74(11): 1328-1335.
10. Robinson TG, Wang X, Arima H, et al. Low- versus standard-dose alteplase in patients on prior antiplatelet therapy the ENCHANTED trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study). Stroke, 2017, 48(7): 1877-1883.
11. Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med, 2016, 375(1): 35-43.
12. Wang YJ, Minematsu K, Wong KS, et al. Ticagrelor in acute stroke or transient ischemic attack in Asian patients: from the SOCRATES trial (acute stroke or transient ischemic attack treated with aspirin or ticagrelor and patient outcomes). Stroke, 2017, 48(1): 167-173.
13. Amarenco P, Albers GW, Denison H, et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol, 2017, 16(4): 301-310.
14. Amarenco P, Albers GW, Denison H, et al. Ticagrelor versus aspirin in acute embolic stroke of undetermined source. Stroke, 2017, 48(9): 2480-2487.
15. Wang Y, Zhao X, Lin J, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA, 2016, 316(1): 70-78.
16. Lin Y, Wang A, Li J, et al. Impact of glycemic control on efficacy of clopidogrel in transient ischemic attack or minor stroke patients with CYP2C19 genetic variants. Stroke, 2017, 48(4): 998-1004.
17. Ernst A, Schlattmann P, Waldfahrer F, et al. 13 Age-specific trends of atrial fibrillation-related ischaemic stroke and transient ischaemic attack,anticoagulant use and risk factor profile in Chinese population--a 15-year study. Laryngorhinootologie, 2017, 96(8): 519-521.
18. Bai Y, Deng H, Shantsila A, et al. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and Meta-analysis. Stroke, 2017, 48(4): 970-976.
19. Anderson CS, Huang Y, Arima H, et al. Effects of early intensive blood pressure-lowering treatment on the growth of hematoma and perihematomal edema in acute intracerebral hemorrhage: the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT). Stroke, 2010, 41(2): 307-312.
20. Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med, 2013, 368(25): 2355-2365.
21. Delcourt C, Sato S, Zhang SH, et al. Intracerebral hemorrhage location and outcome among INTERACT2 participants. Neurology, 2017, 88(15): 1408-1414.
22. Moullaali TJ, Sato S, Wang X, et al. Prognostic significance of delayed intraventricular haemorrhage in the interact studies. J Neurol Neurosurg Psychiatry, 2017, 88(1): 19-24.
23. Li Q, Liu QJ, Yang WS, et al. Island sign: an imaging predictor for early hematoma expansion and poor outcome in patients with intracerebral hemorrhage. Stroke, 2017, 48(11): 3019-3025.

Next Article
Application of artificial intelligence in the field of medicine and neurology

West China Medical Journal

Advances on clinical researches of cerebrovascular diseases in 2017

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content